Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
The Italian Network for Tumor Biotherapy (Network Italiano per la Bioterapia dei Tumori [NIBIT]) Foundation hosted its annual 2020 Think Tank meeting virtually, at which representatives from academic, clinical, industry, philanthropic, and regulatory organisations discussed the role of neoadjuvant immunotherapy for the treatment of cancer. Although the number of neoadjuvant immunothe rapeutic trials is increasing across all malignancies, the Think Tank focused its discussion on the status of neoadjuvant trials in cutaneous melanoma (CM), muscle-invasive urothelial bladder cancer (MIBC), head and neck squamous cell carcinoma (HNSCC), and pancreatic adenocarcinoma (PDAC).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Michele Maio, Christian Blank, Andrea Necchi, Anna Maria Di Giacomo, Ramy Ibrahim, Michael Lahn, Bernard A. Fox, R. Bryan Bell, Giampaolo Tortora, Alexander M.M. Eggermont Tags: Current Perspective Source Type: research
More News: Academia | Adenocarcinoma | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Immunotherapy | Italy Health | Melanoma | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Sexual Abuse | Skin Cancer | Squamous Cell Carcinoma